Magic bullet (medicine)

The magic bullet was a scientific concept developed by a German Nobel laureate Paul Ehrlich in 1900.[1] While working at the Institute of Experimental Therapy (Institut für experimentelle Therapie), Ehrlich formed an idea that it could be possible to kill specific microbes (such as bacteria) that cause diseases without harming the body itself. He named the hypothetical agent as zauberkugel, the magic bullet.[2] He envisioned that just like a bullet fired from a gun to hit a specific target, there could be a way to specifically target invading microbes. His continued research to discover the magic bullet resulted in further knowledge of the functions of the body's immune system, and in the development of Salvarsan, the first effective drug for syphilis, in 1909. His works were the foundation of immunology, and for his contributions he shared the 1908 Nobel Prize in Physiology or Medicine with Élie Metchnikoff.[3]

Ehrlich's discovery of Salvarsan in 1909 for the treatment of syphilis is termed as the first magic bullet. This led to the foundation of the concept of chemotherapy.[4]

Background

Research on antibody

In the early 1890s, Paul Ehrlich started to work with Emil Behring, professor of medicine at the University of Marburg. Behring had been investigating on antibacterial agents, and discovered a diphtheria antitoxin. (For that discovery, Bering was the first recipient of the Nobel Prize in Physiology or Medicine in 1901. Ehrlich was also nominated for that year.[5]) From Behring's work, Ehrlich understood that antibodies produced in the blood could attack invading pathogens without any harmful effect on the body. He speculated that these antibodies act as bullets fired from a gun to target specific microbes. But after further research, he realised that antibodies sometimes failed to kill microbes. This led him to abandon his first idea on magic bullet.[6]

Research on arsenical dye

Ehrlich joined the Institute of Experimental Therapy (Institut für experimentelle Therapie) in 1899, becoming the director of its research institute the Georg–Speyer Haus in 1906. Here his research focused on testing arsenical dyes for killing microbes. Arsenic was an infamous poison, and his attempt was criticised. He was publicly lampooned as an imaginary "Dr Phantasus".[2] But Ehrlich's rationale was that the chemical structure called side chain forms antibodies that bind to toxins (such as pathogens and their products); similarly, chemical dyes such as arsenic compounds could also produce such side chains to kill the same microbes. This led him to propose a new concept called "side-chain theory". (He later, in 1900, revised his concept as "receptor theory".) Based on his new theory, he postulated that in order to kill microbes, "wir müssen chemisch zielen lernen." ("we have to learn how to aim chemically.")[7] His institute was convenient as it was adjacent to a dye factory. He began testing a number of compounds against different microbes. It was during his research that he coined the terms "chemotherapy" and "magic bullet". Although he used the German word zauberkugel in his earlier writings, the first time he introduced the English term "magic bullet" was at a Harben Lecture in London in 1908.[4] By 1901, with the help of Japanese microbiologist Kiyoshi Shiga, Ehrlich experimented with hundreds of dyes on mice infected with trypanosome, a protozoan parasite that causes sleeping sickness. In 1904 they successfully prepared a red arsenic dye they called Trypan Red for the treatment of sleeping sickness.[1]

Discovery of the first magic bullet – Salvarsan

In 1906 Ehrlich developed a new derivative of arsenic compound, which he code-named Compound 606 (the number representing the series of all his tested compounds). The compound was effective against malaria infection in experimental animals.[1] In 1905, Fritz Schaudinn and Erich Hoffmann identified a spirochaete bacterium (Treponema pallidum) as the causative organism of syphilis. With this new knowledge, Ehrlich tested Compound 606 (chemically arsphenamine) on a syphilis-infected rabbit. On 31 August 1909 he found that the rabbit was cured using only a single dose, and just as he expected his magic bullet would be, the rabbit showed no adverse effect. (The normal treatment procedure of syphilis at the time involved two to four years routine injection with mercury.) He then performed experiments on human patients with the same success. After convincing clinical trials, the compound number 606 was given a trade name "Salvarsan", a portmanteau for "saving arsenic".[2] Salvarsan was commercially introduced in 1910, and in 1913, a less toxic form "Neosalvarsan" (Compound 914) was released in the market. These drugs became the principal treatments of syphilis until the arrival of penicillin and other novel antibiotics towards the middle of the 20th century.[1] Ehrlich's research on the magic bullet was the foundation of pharmaceutical research.[7]

References

  1. 1 2 3 4 Tan, SY; Grimes, S (2010). "Paul Ehrlich (1854-1915): man with the magic bullet" (PDF). Singapore Medical Journal. 51 (11): 842–843. PMID 21140107.
  2. 1 2 3 Heynick, F. (2009). "The original 'magic bullet' is 100 years old - extra". The British Journal of Psychiatry. 195 (5): 456–456. doi:10.1192/bjp.195.5.456.
  3. ↑ Schwartz, RS (2004). "Paul Ehrlich's magic bullets". The New England Journal of Medicine. 350 (11): 1079–80. doi:10.1056/NEJMp048021. PMID 15014180.
  4. 1 2 Williams, K. (2009). "The introduction of 'chemotherapy' using arsphenamine - the first magic bullet". Journal of the Royal Society of Medicine. 102 (8): 343–348. doi:10.1258/jrsm.2009.09k036. PMC 2726818Freely accessible. PMID 19679737.
  5. ↑ Chuaire, Lilian; Cediel, Juan Fernando (2009). "Paul Ehrlich: From magic bullets to chemotherapy". Colombia Médica. 39 (3): online.
  6. ↑ Nigel, Kelly; Rees, Bob; Shuter, Paul (2002). Medicine Through Time (2nd ed.). Oxford (UK): Heinemann Educational Publishers. pp. 90–92. ISBN 978-0-435-30841-4.
  7. 1 2 Strebhardt, Klaus; Ullrich, Axel (2008). "Paul Ehrlich's magic bullet concept: 100 years of progress". Nature Reviews Cancer. 8 (6): 473–480. doi:10.1038/nrc2394.
This article is issued from Wikipedia - version of the 9/27/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.